PLA2G4A and COVID-19: Our findings indicate that LHQW and QFPD may treat COVID-19 via pathways associated with inflammation, immunity, apoptosis, oxidative stress, etc. Meanwhile, the unique active compounds (Arctiin, Corymbosin, and Aloe-emodin) in LHQW target neurological disease-related genes (GRM1 and GRM5), and the special active compounds (isofucosterol, baicalein, nobiletin, oroxylin A, epiberberine, and piperlonguminine) in QFPD target immunity- and inflammation-related genes (mTOR and PLA2G4A).